-
Endpoints News3 weeks ago
Genentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trial
Roche’s subsidiary Genentech has called off the late-stage development of a muscle-building drug in two rare genetic conditions, spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy...
-
Fierce Biotech3 weeks ago
Behind the curtain: What Xaira is building after its $1B fundraise
What has Xaira been doing since its $1 billion raise? Xaira COO Jeff Jonker joins “The Top Line” to talk strategy, AI and the company’s long-game...
-
Fierce Biotech3 weeks ago
Intuitive recalls surgical stapler reloads following patient death
This comes in the same week that Intuitive reported a cyberattack, with a phishing incident targeting some of its employees.
-
Uncategorized3 weeks agoFDA finds lack of evidence for dry eye disease drug approval
Aldeyra Therapeutics has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an...
-
Uncategorized3 weeks agoTGA approves trial for first-in-human multiple myeloma therapy
Australia’s Therapeutic Goods Administration (TGA) has approved a first-in-human trial of a T-cell therapy in multiple myeloma. The therapy, developed by HaemaLogiX in collaboration with the Peter MacCallum...
-
STAT News – Biotech3 weeks agoSTAT+: A family’s giving to the Broad Institute’s research tops $1 billion
The Broad Institute of MIT and Harvard is poised to receive a massive injection of cash to fund breakthroughs in the understanding and treatment of bipolar disorder and...
-
STAT News – Biotech3 weeks agoTobacco could get a boost from the farm bill. How does that square with MAHA?
The 2026 farm bill now working its way through Congress contains a number of provisions at odds with the Make America Healthy Again movement, particularly when...
-
STAT News – Biotech3 weeks agoOpinion: Congress must fix the No Surprises Act before it bankrupts patients and employers
Five years ago, President Trump delivered a historic victory for American patients when he signed the No Surprises Act (NSA) into law. The promise of this...
-
STAT News – Biotech3 weeks agoOpinion: How OB-GYNs like me are increasingly able to treat pain from IUDs and other gynecologic procedures
In recent years, a growing outcry has drawn long-overdue attention to a difficult truth: girls’ and women’s pain has too often been dismissed and undertreated in...
-
STAT News – Biotech3 weeks agoSTAT+: Novartis picks up experimental breast cancer therapy for $2B
LONDON — Novartis said Friday it was buying an experimental breast cancer drug from Delaware-based Synnovation Therapeutics for $2 billion upfront. The deal includes includes up...
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
